[Efficacy and safety of cefozopran (CZOP) monotherapy and combination therapy with CZOP and amikacin (AMK) for infections accompanying hematological diseases].
We evaluated efficacy and safety of monotherapy with CZOP (1-2 g x 2/day) and combination therapy with CZOP (1-2 g x 2/day) and AMK (200 mg x 2/day) for infections in patients with hematological diseases. Efficacy was evaluated in 71 patients of monotherapy group and 70 patients of combination therapy group. Underlying diseases were mostly leukemia and lymphoma. Infections included sepsis, suspected sepsis, pneumonia and so on. Efficacy in CZOP monotherapy was excellent in 21 patients (31.3%), good in 23 patients (34.3%), fair in 5 patients (7.5%) and the efficacy rate was 65.7%. On the other hand, in combination therapy, each was 14 patients (21.2%), 23 patients (34.8%), 12 patients (18.2%) and the efficacy rate was 56.1%. Side effects such as eruption were noted in 2 patients. Abnormal laboratory findings were noted in 9 patients. All side effects as well as abnormal laboratory findings were minimal. It was concluded that CZOP monotherapy was effective in the treatment of various infections accompanying hematological diseases.
Urabe
A
A
Division of Hematology, NTT Kanto Medical Center.
Fujita
A
A
Aoki
K
K
Koike
M
M
Kitamura
K
K
Ohbayashi
Y
Y
Oshimi
K
K
Wakabayashi
Y
Y
Kuraishi
Y
Y
Kurihara
I
I
Togawa
A
A
Hoshino
S
S
Ozawa
K
K
Hotta
T
T
Higashihara
M
M
Nagoshi
H
H
Hirai
H
H
Omine
M
M
Asano
S
S
Nishimura
M
M
Suzuki
K
K
Bessho
M
M
Mizoguchi
H
H
Furusawa
S
S
Nonaka
Y
Y
Takaku
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D002511:Cephalosporins / Q000008:administration & dosage*; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D019337:Hematologic Neoplasms / Q000150:complications*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000209:etiology; D018805:Sepsis / Q000188:drug therapy / Q000209:etiology; D000097586:Cefozopran
D000583:Amikacin; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097586:Cefozopran